vTv Therapeutics Inc (VTVT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $78.99M
Last updated: Nov 17, 2026 at 4:10 PM ET
vTv Therapeutics Inc (VTVT) Statistics
vTv Therapeutics (VTVT) has a market cap of $78.99M and an enterprise value of $1.83M. Revenue grew 216458.82% over the last 12 months from the 12 months before. Its share count is up 54.22% from a year earlier.
Total Valuation
Enterprise value is 97.69% below the market cap, as cash exceeds debt.
| Market Cap | $78.99M |
|---|---|
| Enterprise Value | $1.83M |
| Latest price (Nov 17, 2026) | $17.29 |
Key Dates
The next earnings report is expected on Mar 8, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| Forward P/S | 2.6x |
|---|---|
| P/B Ratio | 3.1x |
Price Statistics
The stock is down 43.86% over 52 weeks and trades 36.94% below its 50-day average.
| Beta (1Y) | 1.41 |
|---|---|
| 52-Week Change | -43.86% |
| 1-Month Change | -35.82% |
| 3-Month Change | -47.44% |
| 6-Month Change | -52.62% |
| 5-Year Change | -56.00% |
| 10-Year Change | -88.33% |
| Total Return (1Y) | -43.86% |
| Total Return (3Y CAGR) | +5.21% |
| Total Return (5Y CAGR) | -21.73% |
| Return vs SPY (1Y) | -54.14% |
| Max Drawdown (1Y) | -59.52% |
| Max Drawdown (3Y) | -59.52% |
| Sharpe Ratio (1Y) | -0.77 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $27.42 |
| 200-Day Average | $32.70 |
| 52-Week Range | $17.28 to $44.00 |
| RSI (14 Days) | 18.0 |
| Average Volume (20 Days) | 22.58K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 11.19x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 11.19x |
|---|---|
| Quick Ratio | 11.19x |
| Debt / Equity | 0.00x |
Returns and Efficiency
| ROA (5Y Average) | -94.01% |
|---|---|
| Asset Turnover | 0.41x |
Scores
VTVT has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $36.81M over the last 12 months.
| Revenue | $36.81M |
|---|---|
| Revenue Growth (YoY) | +216458.82% |
| Gross Profit | $36.84M |
| Operating Income | -$10.98M |
| Pretax Income | -$7.68M |
| Net Income | -$7.68M |
| Reported EPS (TTM) | -$0.92 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 88.65% of the $78.61M in total assets.
| Cash and Equivalents | $77.16M |
|---|---|
| Total Debt | $0 |
| Net Cash | $77.16M |
| Net Cash Per Share | $6.21 |
| Working Capital | $71.58M |
| Shareholder Equity | $69.69M |
| Book Value Per Share | $5.61 |
| Total Assets | $78.61M |
| Total Liabilities | $8.92M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$21.73M |
|---|---|
| FCF Per Share | -$5.50 |
| Depreciation and Amortization | $5.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -29.82%.
| Gross Margin | 100.06% |
|---|---|
| Operating Margin | -29.82% |
| Pretax Margin | -20.86% |
| Net Margin | -20.86% |
Stock Splits
The last split was a 1-for-40 reverse split on Nov 21, 2023.
| Last Split Date | Nov 21, 2023 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:40 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About VTVT
What is VTVT's market cap?
vTv Therapeutics has a market cap of $78.99M. Its enterprise value, which adds debt and subtracts cash, is $1.83M.
How many shares of VTVT are outstanding?
vTv Therapeutics has 12.42M shares outstanding. The count is up 54.22% from a year earlier.
Does VTVT pay a dividend?
No. vTv Therapeutics does not pay a dividend.
How much debt does VTVT have?
vTv Therapeutics has $0 of total debt and $77.16M of cash and equivalents, a net cash position of $77.16M.
VTVT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors